Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 June 2024 | Story Precious Shamase | Photo Supplied
Prof Richard Ocaya
Prof Richard Ocaya, Associate Professor from the Physics Department.

Prof Richard Ocaya from the Faculty of Natural and Agricultural Sciences at the University of the Free State (UFS) Qwaqwa  Campus has achieved a significant milestone with a newly patented invention. This patent, developed in collaboration with researchers from Turkey and Saudi Arabia, is the result of work that began in 2017, focusing on a special material known as graphitic carbon nitride.

This breakthrough in temperature measurement technology aligns perfectly with the university's Vision 130 commitment to innovation and addressing global challenges. The new device offers a unique solution to a longstanding issue in the field, providing accurate temperature measurements across an extremely wide range. Existing solutions often require multiple devices, leading to increased costs and reduced accuracy, but this invention simplifies the process.

The device, based on a combination of graphitic carbon nitride and silicon, can measure temperatures from -250°C to 250°C with exceptional consistency and linearity. This range and accuracy set it apart from current technologies, making it suitable for various applications, from standard temperature measurement to specialized settings involving extreme temperatures. It could be especially valuable in deep-space exploration, where equipment faces drastic temperature fluctuations.

The patent underscores the university's commitment to fostering collaborative research, a key aspect of Vision 130. Prof Ocaya attributes the success of the invention to the robust nature of the team, established in 2015. The team is now seeking to commercialize the technology by licensing it to a suitable partner, with organizations like NASA expected to show significant interest.

Prof Ocaya advises other academics considering patenting their inventions to ensure the patent solves a real problem uniquely and is based on sound principles. This makes the invention reproducible and protects it from being copied, assigning exclusive rights to the patent holder. Patenting allows for either manufacturing the devices or licensing them to third parties for royalties and profit. He notes that the main consideration is that the innovation must be practical and solve a specific problem in a novel and commercially viable way. He also acknowledges the challenge many academics face, as the "publish or perish" mentality often leads to choosing scientific articles over patents.

Despite securing the patent, Prof Ocaya and his team continue their research efforts, exploring new possibilities while balancing practical research with academic pursuits. He believes the invention will significantly impact the field of temperature measurement, being integrated into many new designs requiring such measurements.

The university proudly supports this innovative research and anticipates its real-world impact, furthering Vision 130's commitment to increasing UFS's research capacity and capability.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept